News - Page 193 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article Psilocybin Data Study Agreement Reached Between Silo Wellness and Ehave Using Brain Scientific Mapping Neurocap

Psilocybin Data Study Agreement Reached Between Silo Wellness and Ehave Using Brain Scientific Mapping Neurocap

Post published:March 24, 2021
Post category:Press Release

Read more about the article Numinus Deep Dive: Developing and Delivering Psychedelic-Assisted Psychotherapies

Numinus Deep Dive: Developing and Delivering Psychedelic-Assisted Psychotherapies

Post published:March 23, 2021
Post category:Analysis Editorial

Read more about the article Mindset Pharma and InterVivo Solutions to Jointly Develop Advanced Cooperative Psychedelics Evaluation Platform (“Cope”); Cope Expected to Be World’s First in Vivo Psychedelic Benchmark Data Set

Mindset Pharma and InterVivo Solutions to Jointly Develop Advanced Cooperative Psychedelics Evaluation Platform (“Cope”); Cope Expected to Be World’s First in Vivo Psychedelic Benchmark Data Set

Post published:March 23, 2021
Post category:Press Release

Read more about the article COMPASS Pathways granted two US patents

COMPASS Pathways granted two US patents

Post published:March 23, 2021
Post category:Press Release

Read more about the article Mydecine Innovations Group Announces Migration to NEO Exchange

Mydecine Innovations Group Announces Migration to NEO Exchange

Post published:March 23, 2021
Post category:Press Release

Read more about the article Optimi Health Large Scale Multi-Purpose Mushroom Facility Advances Towards Completion and Licensing

Optimi Health Large Scale Multi-Purpose Mushroom Facility Advances Towards Completion and Licensing

Post published:March 23, 2021
Post category:Press Release

Read more about the article Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)

Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)

Post published:March 22, 2021
Post category:Press Release

Read more about the article Mindset Pharma Announces $5 Million Bought Deal Financing

Mindset Pharma Announces $5 Million Bought Deal Financing

Post published:March 22, 2021
Post category:Press Release

Read more about the article MindMed Announces Inclusion in FTSE Russell Indexes

MindMed Announces Inclusion in FTSE Russell Indexes

Post published:March 22, 2021
Post category:Press Release

Numinus Announces Closing of $40-Million Bought Deal Financing

Post published:March 19, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.